Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
NEW YORK, September 24, 2009 — Boehringer Ingelheim, and its US animal health business Boehringer Ingelheim Vetmedica, Inc., has entered into an agreement with Pfizer to acquire certain assets of Wyeth’s Fort Dodge Animal Health business upon the closing of the global Pfizer-Wyeth merger. Covington & Burling LLP represented Boehringer Ingelheim on the transaction. Boehringer Ingelheim, based in Ingelheim, Germany, is a family-owned company founded in 1885 that is one of the world’s 20 leading pharmaceutical companies and is committed to researching, developing, manufacturing, and marketing novel products of high therapeutic value for human and veterinary medicine. Pfizer, the world’s largest research-based biomedical and pharmaceutical company, discovers and develops innovative medicines to treat and help prevent disease for both people and animals. The Covington team representing Boehringer Ingelheim included lawyers based in Washington, New York, London, and San Francisco and was led by corporate partners John Hurvitz, Stephen Infante, and Catherine Dargan and of counsel Lucinda Osborne, with associates Maarika Liivak, Andrew Hyman, and Elizabeth DeYoung. Also advising on the transaction were of counsel Jeannie Perron (life sciences-regulatory), partner Amy Toro and associate Emily Mason (life sciences-commercial), special counsel Marie Lavalleye (trademarks), special counsel Natalie Derzko (patents), partner Robert Newman (employee benefits), associate Jenna Wallace* (employee benefits), of counsel Heather Haberl (real estate), partner Corinne Goldstein (environmental), partner Robert Heller (tax), and associates Thomas Cosgrove, Christina Chung and Courtney Macdonald** (intellectual property-commercial). *Not yet admitted to practice. **Admitted to the Virginia bar; not admitted to practice in New York.